
|Videos|November 14, 2020
AAO: Considerations when using anti-VEGF for treating AMD
Author(s)OTE Staff Reports
Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
Advertisement
Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5






















